Skip to main content
Clinical Trials/NCT05400928
NCT05400928
Unknown
Not Applicable

The Effect and Safety of Pulsed Field Ablation (PFA) in Patients With Paroxysmal Atrial Fibrillation (PAF)-A Prospective Multicenter Single-arm Study

Tongji Hospital1 site in 1 country144 target enrollmentJuly 5, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Paroxysmal Atrial Fibrillation
Sponsor
Tongji Hospital
Enrollment
144
Locations
1
Primary Endpoint
Immediate success rate
Last Updated
3 years ago

Overview

Brief Summary

This study is aimed to evaluate the Efficacy and Safety of Pulsed Field Ablation (PFA) in Patients with Paroxysmal Atrial Fibrillation (PAF)

Detailed Description

This clinical trial is a prospective, multi-center and single-arm Study. It will be carried out in 3 or more clinical trial institutions, and eligible patients with paroxysmal atrial fibrillation are enrolled. For those patients recruited, pulmonary vein isolation will be performed using pulsed field ablation device (Sichuan Jinjiang Electronic Technology Co., Ltd. Chengdu, China). The safety and efficacy of pulsed field ablation(PFA) in Patients with Paroxysmal Atrial Fibrillation (PAF) will be studied using ring-shaped pulsed field ablation catheter

Registry
clinicaltrials.gov
Start Date
July 5, 2021
End Date
December 31, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dao Wen Wang

Professor

Tongji Hospital

Eligibility Criteria

Inclusion Criteria

  • Paroxysmal Atrial Fibrillation (PAF)

Exclusion Criteria

  • A history of atrial fibrillation ablation;
  • Left ventricular ejectfraction(LVEF)\<35%
  • Left Atrium(LA)(echocardiography)\>55mm
  • Thrombus in the left atrial or heart before surgery
  • New York Heart Association(NYHA) grade Ⅲ-Ⅳ
  • second or third degree atrioventricular block
  • Significant congenital heart defects (e.g. atrial septal defect or severe pulmonary vein stenosis, but except foramen ovale)
  • Prosthetic valves
  • Pacemakers or defibrillators (ICD)
  • Hypertrophic cardiomyopathy, chronic obstructive pulmonary disease or myxoma

Outcomes

Primary Outcomes

Immediate success rate

Time Frame: during procedure

Procedural success for PAF is defined as the achievement of complete pulmonary venous electrical isolation

Secondary Outcomes

  • Procedural success rate at 12 months after procedure(between 3 months and 12 months after ablation)
  • The occurrence of hospitalizations or emergency department visit due to symptoms of atrial arrhythmia at 6-month and 12-month follow-up(at 6-month and 12-month)
  • Evaluation of a disposable cardiac pulsed electric field ablation catheter(baseline)
  • Evaluation of pulsed electric field ablation instrument(baseline)

Study Sites (1)

Loading locations...

Similar Trials